Trends in liver failure-related mortality among middle-aged and older adults with digestive system malignant tumors in the United States, 1999–2023 - Scorecard - MDSpire
Advertisement
Trends in liver failure-related mortality among middle-aged and older adults with digestive system malignant tumors in the United States, 1999–2023
Clinical Scorecard: Shifts in Liver Failure Mortality Rates Among Middle-Aged and Older Adults with Digestive System Malignancies in the United States, 1999–2023
At a Glance
Category
Detail
Condition
Liver failure related to digestive system malignancies
Key Mechanisms
Liver failure may occur due to primary hepatic malignancy, metastatic burden, treatment-related hepatotoxicity, or preexisting chronic liver disease.
Target Population
Middle-aged and older adults (aged ≥45 years) with digestive system malignant tumors (DSMTs)
Care Setting
Population-based mortality surveillance
Key Highlights
82,796 liver failure-related deaths among patients aged ≥45 years with DSMTs from 1999 to 2023.
Annual deaths declined from 4,131 in 1999 to 3,250 in 2023 (−21.33%).
Age-adjusted mortality rates decreased from 4.34 to 2.08 per 100,000 population.
Mortality decline was uneven across demographic and geographic strata.
Males exhibited higher mortality rates than females, with significant increases among Hispanic individuals.
Guideline-Based Recommendations
Diagnosis
Liver failure identified using ICD-10 code K72 under a multiple cause-of-death framework.
Management
Continued attention to liver function monitoring and liver disease risk assessment.
Monitoring & Follow-up
Targeted surveillance in high-risk populations and regions.
Risks
Increased mortality risks associated with liver failure in patients with DSMTs.
Patient & Prescribing Data
Patients aged ≥45 years with digestive system malignant tumors.
Liver failure can limit the feasibility of subsequent antitumor therapies.
Clinical Best Practices
Implement liver function monitoring for patients with DSMTs.
Assess liver disease risk in older patients with DSMTs.
Conduct targeted public health interventions in regions with high liver failure mortality.
